Sexual Health
PT-141
Bremelanotide · Vyleesi
Boosts sexual desire through the brain rather than blood flow, which sets it apart from typical erectile dysfunction drugs. It has one genuine approval — low desire in women who haven't reached menopause. Everything else, including its use in men, is off-label.
Central-acting arousal — approved for one population, widely extrapolated for another.
How well studied
Tier Guide: A = Well studied, B = Some good studies, C = Early evidence & D = Barely studied
Tested in people, but in smaller or fewer studies. A decent picture, just less certain.
Heightened caution: this compound carries unresolved regulatory, safety or supply-chain concerns in the UK. Nothing here is a recommendation to use it.
How it works
Acts in the brain, on the pathways behind desire and arousal — a different route entirely from drugs like Viagra, which work on blood flow.
Acts on in the brain to boost arousal and desire, a different pathway from blood-flow-based ED treatments like inhibitors.
Reported benefits
- Boosts central arousal and desire pathway
- Works independently of blood flow — complements PDE5 inhibitors rather than duplicating them
Who it's typically used for
Timeline to results
Dosage
Approved dose (1.75mg) is for women's HSDD only, and not licensed in the UK regardless — no established male dose exists.
Side effects
- Nausea~40% on first dose, drops below 10% by dose 5-6
- Flushingreported
- Headachereported
- Transient blood pressure rise2-3mmHg
Getting it in the UK
No UK doctor can prescribe this at all. It's sold online labelled 'not for human use' — nobody is checking what's actually in it, or whether it's safe.
MHRA: the UK government body that checks a medicine is safe and actually works before doctors are allowed to prescribe it.
Content freshness
- Last reviewed
- 11 Aug 2026
- Regulatory status last checked
- 11 Aug 2026